Paradigm Biopharmaceuticals Ltd (ASX:PAR) has appointed Helen Fisher to its board as a non-executive director and chair of the audit and risk committee effective February 23, 2021.
With a deep understanding of the health care sector, combined with her first-hand commercial experience and technical background in law, science and finance, Fisher will bring the necessary skills and experience to the Paradigm board for future growth and globalisation.
The company continues to progress toward submission of the Investigational New Drug (IND) for Zilosul® and is focused on the implementation of the osteoarthritis clinical program to support commercialisation.
“Pricing and taxation guidance”
Fisher has provided strategic tax advice to publicly listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP and supply chain management.
Paradigm CEO and chairman Paul Rennie said: “We are delighted to have Helen join our board and her experience in the health care sector will be important as Paradigm begins to operationalise its harmonised clinical trials in the USA, Australia and Europe.
“Helen will also be able to provide guidance and oversee our international pricing strategy for Zilosul®, including on transfer pricing and multi-jurisdictional tax matters.”
Extensive experience
Fisher is currently CEO and managing director of Bio Capital Impact Fund (BCIF) and a non-executive director (NED) and chair of the audit and risk committee of Calix Ltd (ASX:CXL), a company with a platform technology with applications in climate change, water management, biotech and pharmaceutical areas.
Fisher previously held a NED and chair of the audit and risk committee position at Sienna Cancer Diagnostics Limited before it was acquired by BARD1 Life Sciences Ltd (ASX:BD1) (FRA:EGQ).
Prior to establishing BCIF, she was a partner of Deloitte and led Deloitte’s life sciences practice in Australia for 5 years, and also specialised in the financial services sector, servicing some of the largest global and Australian banks and funds, and advising on several significant M&A transactions.